Artwork

Content provided by Lauren Bongiorno. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Lauren Bongiorno or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

96. Glucagon: busting the myths of this rescue drug to save lives and reform healthcare education with Xeris CEO Paul Edick

35:19
 
Share
 

Manage episode 386729426 series 3332851
Content provided by Lauren Bongiorno. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Lauren Bongiorno or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Ever heard someone say you only need glucagon when you’re passed out? In my sit down with Xeris CEO Paul Edick, we discussed the misperceptions and myths surrounding glucagon as a rescue prescription. From the lack of education within the healthcare community to the patients’ misinformation themselves, this is a call to action for patient advocacy and advocates to get everyone with diabetes on a rescue glucagon like Gvoke. That starts with learning proper usage and correct knowledge. This episode could save lives, and I am fully on board with sharing the Gvoke mission!

Time Stamps:

  • (03:20) Paul’s journey to becoming CEO of Xeris and the “elegance” of Xeris technology
  • (04:48) The growth of Xeris
  • (06:41) What is glucagon?
  • (07:56) The fallacy and myths around glucagon and its proper use.
  • (09:32) Why did it take so long to innovate glucagon?
  • (10:50) The statistics of hypoglycemia
  • (12:33) What is considered a severe low and clinical trials
  • (15:37) Using education to combat fears of glucagon and going low
  • (18:15) The number one battle Xeris faces in getting Gvoke into more hands
  • (20:16) Xeris’ role in educating the healthcare community on proper usage and knowledge
  • (22:43) A Call to Action for patient advocacy and advocates
  • (23:33) Standardized procedures for discussing rescue glucagon
  • (26:00) What Xeris learned from bringing in social influencers to ask questions
  • (29:08) The future of Xeris, their mission, and the startling statistical comparison to EpiPen for allergies

What to do now:

  1. Follow me @lauren_bongiorno and @riselyhealth on Instagram to stay in the loop for when new episodes drop.
  2. Learn more and apply for the January 2024 Decide and Conquer Bootcamp HERE.


Disclaimer: Nothing you hear on the Reclaim your Rise podcast should be a substitute for personalized professional medical advice. Please always consult your physician or other medical professional before making any changes to your diet, insulin dosages, or healthcare plan.

  continue reading

131 episodes

Artwork
iconShare
 
Manage episode 386729426 series 3332851
Content provided by Lauren Bongiorno. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Lauren Bongiorno or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Ever heard someone say you only need glucagon when you’re passed out? In my sit down with Xeris CEO Paul Edick, we discussed the misperceptions and myths surrounding glucagon as a rescue prescription. From the lack of education within the healthcare community to the patients’ misinformation themselves, this is a call to action for patient advocacy and advocates to get everyone with diabetes on a rescue glucagon like Gvoke. That starts with learning proper usage and correct knowledge. This episode could save lives, and I am fully on board with sharing the Gvoke mission!

Time Stamps:

  • (03:20) Paul’s journey to becoming CEO of Xeris and the “elegance” of Xeris technology
  • (04:48) The growth of Xeris
  • (06:41) What is glucagon?
  • (07:56) The fallacy and myths around glucagon and its proper use.
  • (09:32) Why did it take so long to innovate glucagon?
  • (10:50) The statistics of hypoglycemia
  • (12:33) What is considered a severe low and clinical trials
  • (15:37) Using education to combat fears of glucagon and going low
  • (18:15) The number one battle Xeris faces in getting Gvoke into more hands
  • (20:16) Xeris’ role in educating the healthcare community on proper usage and knowledge
  • (22:43) A Call to Action for patient advocacy and advocates
  • (23:33) Standardized procedures for discussing rescue glucagon
  • (26:00) What Xeris learned from bringing in social influencers to ask questions
  • (29:08) The future of Xeris, their mission, and the startling statistical comparison to EpiPen for allergies

What to do now:

  1. Follow me @lauren_bongiorno and @riselyhealth on Instagram to stay in the loop for when new episodes drop.
  2. Learn more and apply for the January 2024 Decide and Conquer Bootcamp HERE.


Disclaimer: Nothing you hear on the Reclaim your Rise podcast should be a substitute for personalized professional medical advice. Please always consult your physician or other medical professional before making any changes to your diet, insulin dosages, or healthcare plan.

  continue reading

131 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide